GSK CEO Emma Walmsley with Endpoints' Drew Armstrong at the Financial Times' Global Pharma and Biotech Summit (courtesy Financial Times)

November 6, 2024 01:49 PM EST

China

Pharma

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Drew Armstrong

Executive Editor

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley believes her company can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biotech industry worries over potential for RFK Jr. ally as FDA pick

New Trump era could be a boon for biopharma M&A, dealmaking

California voters say yes to restrictions around 340B spending

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Studies show how once-obscure DNA circles drive cancer, and maybe even how to stop them

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Executive Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China